OSE Immunotherapeutics met à jour l’information sur les procédures en cours

Group 1 - OSE Immunotherapeutics announced that the Nantes Commercial Court rejected motions from a group of shareholders seeking to retract an order that adjourned the annual general meeting [1] - The company has initiated an accelerated legal procedure against the same group of shareholders, with a hearing scheduled for September 8, 2025, to address the regularity of their concerted action declaration [2] - OSE Immunotherapeutics plans to hold its annual shareholders' meeting on September 30, 2025, subject to the outcome of the ongoing legal proceedings [3] Group 2 - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, aiming to meet unmet patient needs [4]